RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Apple Turns 50: From Garage Startup to AI Crossroads 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
 and Lead Plaintiff Deadline - December 23, 2016 - EconoTimes)
NEW YORK, Dec. 19, 2016 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Xerox Corporation (“Xerox” or the “Company”) (NYSE:XRX) and certain of its officers. The class action is on behalf of a class consisting of all persons or entities who purchased Xerox securities between April 23, 2012 through October 23, 2015, inclusive (the “Class Period”).
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Xerox’s existing Health Enterprise projects were experiencing major delays and cost overruns; (2) Xerox would not be unable to deliver Health Enterprise implementations at workable profits; and (3) consequently, Xerox’s statements regarding its business, operations, and prospects lacked a reasonable basis.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/xrx or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email [email protected]. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Xerox you have until December 23, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]
